## **Core Concept**
Hepatic amoebiasis is a condition caused by the protozoan parasite *Entamoeba histolytica*, which primarily affects the liver. The treatment involves targeting the parasite with specific antimicrobial agents. Understanding the lifecycle of the parasite and its pathogenic mechanisms is crucial for selecting the appropriate treatment.

## **Why the Correct Answer is Right**
The correct approach to treating hepatic amoebiasis involves using medications that are effective against *E. histolytica*. The first-line treatment typically includes tissue amoebicides, which are drugs that can penetrate and act within the liver tissue. **Metronidazole** is a commonly used tissue amoebicide because it achieves high concentrations in the liver and is effective in killing the parasite.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Without the specific details of Option A, we cannot directly address its incorrectness, but generally, incorrect options might include drugs that are not effective against *E. histolytica* in the liver or are not considered first-line treatments.
- **Option B:** Similarly, without specifics, if Option B suggests a treatment that is not primarily used for hepatic amoebiasis or is less effective compared to metronidazole, it would be considered incorrect.
- **Option C:** If Option C proposes a treatment that might be used for intestinal amoebiasis but not specifically targeted for hepatic involvement, it would not be the best choice.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that for hepatic amoebiasis, **metronidazole** is considered a first-line treatment due to its efficacy and ability to penetrate liver abscesses. Following treatment with a tissue amoebicide, a luminal amoebicide like **paromomycin** may be used to eradicate the parasite from the intestinal lumen and prevent recurrence.

## **Correct Answer:** . Metronidazole